"We're buyers of dips": Mike Wilson, strategist at Morgan Stanley ( MS 1.58%), said he expects a "modest pullback in the ...

Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

Stocks surged Monday, led by tech sector gains, as the market recovered from a steep decline at the end of last week that was sparked by renewed concerns about tariffs and the health of the economy.

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Novo Nordisk will hold its Q2 FY2025 earnings call on Wednesday, before the market opens. The company s having a terrible ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178 % ...